Oxford Biomedica plc (LON:OXB) Given Consensus Recommendation of “Moderate Buy” by Analysts

Oxford Biomedica plc (LON:OXB) has been given a consensus rating of “Moderate Buy” by the seven ratings firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is GBX 687.

OXB has been the subject of several recent analyst reports. Stifel Nicolaus reaffirmed a “buy” rating and issued a GBX 950 target price on shares of Oxford Biomedica in a research report on Wednesday, March 11th. Jefferies Financial Group initiated coverage on Oxford Biomedica in a research report on Monday, March 23rd. They issued a “buy” rating and a GBX 827 target price for the company.

Oxford Biomedica Stock Performance

Shares of Oxford Biomedica stock opened at GBX 621.04 on Monday. The stock has a market cap of £750.96 million, a PE ratio of -23.07 and a beta of 1.10. The business has a fifty day simple moving average of GBX 604.98 and a 200-day simple moving average of GBX 664.32. The company has a quick ratio of 1.67, a current ratio of 2.20 and a debt-to-equity ratio of 116.74. Oxford Biomedica has a 12 month low of GBX 305.50 and a 12 month high of GBX 952.

Oxford Biomedica (LON:OXB) last issued its earnings results on Thursday, March 26th. The biopharmaceutical company reported GBX (26.92) EPS for the quarter. Oxford Biomedica had a negative return on equity of 48.56% and a negative net margin of 17.85%. On average, sell-side analysts anticipate that Oxford Biomedica will post -31.0799998 EPS for the current fiscal year.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.